Početna stranicaGRFS • NASDAQ
add
Grifols SA - ADR ADR Class B
Preth. zaklj. cijena
8,78 $
Dnevni raspon
8,80 $ - 8,90 $
Godišnji raspon
6,19 $ - 11,14 $
Tržišna kapitalizacija
7,56 mlr. USD
Prosječna količina
680,92 tis.
P/E omjer
21,22
Prinos dividende
1,99 %
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (EUR) | ruj 2025.info | Godišnja promjena |
|---|---|---|
Prihod | 1,87 mlr. | 4,04 % |
Operativni troškovi | 370,34 mil. | −1,71 % |
Neto dohodak | 126,96 mil. | 145,62 % |
Neto profitabilnost | 6,81 | 136,46 % |
Zarada po dionici | — | — |
EBITDA | 484,03 mil. | 3,41 % |
Efektivna porezna stopa | 27,61 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (EUR) | ruj 2025.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 825,48 mil. | 2,32 % |
Ukupna imovina | 19,85 mlr. | −2,12 % |
Ukupne obveze | 12,31 mlr. | 0,14 % |
Ukupni kapital | 7,55 mlr. | — |
Dionice u optjecaju | 680,51 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 1,15 | — |
Povrat imovine | 4,81 % | — |
Povrat kapitala | 7,37 % | — |
Tok novca
Neto promjena novca
| (EUR) | ruj 2025.info | Godišnja promjena |
|---|---|---|
Neto dohodak | 126,96 mil. | 145,62 % |
Gotovina od poslovanja | 325,40 mil. | 8,61 % |
Gotovina iz ulaganja | −122,68 mil. | 37,53 % |
Gotovina iz financiranja | −138,76 mil. | 91,08 % |
Neto promjena novca | 62,27 mil. | 104,24 % |
Slobodan tok novca | 853,30 mil. | 218,17 % |
Više
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceuticals, the company is also in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Grifols also provides biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products.
Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
Glavni izvršni direktor
Osnovano
18. stu 1940.
Web-lokacija
Zaposlenici
23.800
